High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia


This pilot clinical trial studies whether using high throughput drug sensitivity and genomics data is feasible in developing individualized treatment in patients with multiple myeloma or plasma cell leukemia that has come back or does not respond to treatment. High throughput screen tests many different drugs that kill multiple myeloma cells in individual chambers at the same time. Matching a drug or drug combination to a patient using high throughput screen and genetic information may improve the ability to help patients by choosing drugs that work well for their disease.

SparkCures ID 1069
Enrollment 30 Patients
Trial Sponsors
  • Fred Hutchinson / University of Washington Cancer Consortium
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Diagnosis of multiple myeloma with documented relapsed or refractory disease according to International Myeloma Working Group (IMWG) criteria, or relapsed/refractory plasma cell leukemia
  • Collection of a bone marrow, fluid or tissue sample that is expected to have enough cells to run the assay
  • Measurable disease defined by one of the following:
    • Serum monoclonal protein >= 0.5 g/dL by serum protein electrophoresis (SPEP)
    • >= 200 mg/monoclonal protein in urine on 24 hr urine protein electrophoresis (UPEP)
    • Involved serum free light chain (FLC) >= 10 mg/dL and abnormal involved:uninvolved ratio
    • Plasma cytomas that are palpable per exam or measurable per standard radiologic review
    • Circulating plasma cells >= 2,000 if diagnosis of plasma cell leukemia
  • Minimum of 3 prior lines of therapy including an immunomodulatory drug (IMiD) and a proteasome inhibitor (PI)
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3
  • Female patients of child bearing potential and non-vasectomized male patients agree to practice appropriate methods of birth control
  • Ability to understand purpose and risks of the study and provide signed and dated informed consent, and authorization to use protected health information
  • Expected survival is > 100 days
  • Adequate organ function as determined by the investigator

Exclusion Criteria:

  • Mucosal or internal bleeding, or platelet transfusion refractory
  • Any medical conditions that would impose excessive risk to the patient, or would adversely affect his/her participation in the study
  • Known active infection requiring antibiotics within 7 days of initiation of study treatment, unless considered controlled in the opinion of the investigator
  • Other malignancy with life expectancy < 1 year due to the other malignancy
  • Pregnant or breast feeding women
  • Serious psychiatric illness, alcoholism, or drug addiction
  • Human immunodeficiency virus (HIV), or active hepatitis B or C infection
  • Previous treatments for multiple myeloma (MM) within 2 weeks of initiation of study treatment
  • Prior autologous or allogeneic stem cell transplantation (SCT) within 12 weeks of initiation of study treatment
  • Prior allogeneic hematopoietic cell transplantation (HCT) with active graft versus host disease (GVHD) on therapeutic dosing of immunosuppression or prednisone > 20 mg daily equivalent
  • Prior major surgical procedure or radiation treatment within 2 weeks of initiation of study treatment (not including limited radiation used for palliation of bone pain)

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.


There are no resources, links or videos to display for this clinical trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message